Foulkes et al. (1) reported that the expression of cytokeratin 5/6, indicating a basal epithelial phenotype, was statistically significantly associated with germline BRCA1 mutations in estrogen receptor (ER)-and erbB2-negative invasive breast cancers. It has recently been shown that the epidermal growth factor receptor (EGFR) is often expressed in basal-type ("stem") cells of the breast (2) , extending the phenotype of basal cells to ER -/erbB2 -/EGFR ϩ breast cells. We examined the expression of EGFR by immunohistochemistry in the invasive breast cancers from 21 proven carriers of BRCA1 germline mutations and five proven carriers of BRCA2 germline mutations, as well as from a control group of 430 invasive breast cancers from patients unselected for a family history of breast cancer. Only clear membrane staining for EGFR was considered as overexpression. Of the 21 BRCA1-related breast cancers, 14 (67%) showed EGFR overexpression, 19 (90%) were ER negative, and 17 (81%) were erbB2 negative. Eleven (52%) of 21 tumors were ER -/erbB2 -/EGFR ϩ . All five (100%) breast cancers in BRCA2 mutation carriers showed EGFR overexpression, four (80%) were ER negative, and three (75%) of four were erbB2 negative (one could not be characterized Several reports have established that sporadic breast carcinomas with expression of basal cell (myoepithelial cell) markers, such as P-cadherin and high molecular weight cytokeratins CK5/6, CK14, and CK17, show specific morphologic and prognostic characteristics (1, 2) . In cDNA studies, Perou et al. than 65 years. In addition, we have recently reported that the expression of P-cadherin is also most common in BRCA1-related cancers than in familial BRCA2-related and non-BRCA1/2-related cancers (7) .
To further test the hypothesis that the basal cell phenotype is BRCA1-related, we analyzed the basal cytokeratin CK5/6 and the ductal cytokeratin CK8 in infiltrating ductal carcinomas (IDCs) from 20 patients with a BRCA1 mutation (mean age ϭ 42 years) and 14 patients with a BRCA2 mutation (mean age ϭ 42.6 years) genes. The morphological and some immunohistochemical features of this series have been recently published (7). In addition, 59 patients with non-familial IDCs (mean age ϭ 42.6 years) were studied, as an agematched control group. All tumors were included in a tissue microarray and subjected to immunohistochemistry as previously described (7) . Positive CK5/6 expression was as reported by Foulkes et al. (6) . Reduced expression of CK8 was recorded when less than 50% of tumor cells expressed this marker.
In our series, CK5/6 was expressed in nine (45%) of 20 BRCA1-related carcinomas, one (7%) of 14 BRCA2-related carcinomas, and five (8%) of 59 sporadic breast carcinomas, respectively (PϽ.001) (Fig. 1) . The ER-negative/ HER2-negative phenotype was present in 15 (75%), one (7%), and eight (14%) of the BRCA1-related, BRCA2-related, and sporadic breast cancers, respectively (PϽ.001). The complete ERnegative/HER2-negative and CK5/6-positive phenotype was observed in nine (45%), one (7%), and three (5%) BRCA1-related, BRCA2-related, and sporadic breast carcinomas, respectively (PϽ.001). When we considered only cases with an ER-negative/ HER2-negative phenotype, CK5/6 was expressed in nine (60%) of 15 BRCA1-related carcinomas and three (37%) of eight sporadic breast carcinomas, although this difference was not statistically significant, in contrast to the results of Foulkes et al. (6) . The smaller number of case patients and the different ethnic population analyzed in our study may explain the discrepancies between series. In this sense, most case patients in the study of Foulkes et al. (6) were probably related to the BRCA1 Ashkenazi Jewish founder mutations, which could be associated with a more homogeneous breast cancer phenotype. In any case, the present study supports the existence of a subtype of highgrade, ER-negative/HER2-negative breast carcinomas with a basal phenotype that occurs more frequently in BRCA1-related than in sporadic carcinomas. This phenotype can also occur, although very infrequently, in BRCA2-related breast cancer.
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We note with interest that data from Palacios et al. broadly support our original observation, and that the data from van der Groep et al. extend our findings to include other basal-associated markers, in this case, epidermal growth factor receptor (EGFR). It is notable that van der Groep et al. found that BRCA2-related breast cancers also tended to share the basal epithelioid phenotype previously identified only in BRCA1-related breast cancers. This result should be interpreted cautiously, particularly because only four tumors were studied and because all four BRCA2 tumors were estrogen receptor (ER)-negative, which is unusual. Most BRCA2-related breast cancers are ER-positive (1). Moreover, the reports of Sørlie et al. (2) and Palacios et al. do not suggest that the basal phenotype of BRCA1-related breast cancer is likely to be extendible to BRCA2-related breast cancer.
The data provided by Palacios et al. suggest that the complete ER/erbB2-negative, cytokeratin (CK) 5/6-positive phenotype may not be quite so discriminatory of a BRCA1 mutation if age is taken into account. However, in light of our findings and those reported by Palacios et al. and van der Groep et al. we suggest that basal markers, such as CK5/6 and its partner CK14, as well as P-cadherin and EGFR, be evaluated further as first-line immunohistochemical tests for the presence of a germ-line BRCA1 mutation. The finding of van der Groep et al. that the BRCA1-related basal phenotype can be extended to include the basal-associated marker EGFR is consistent with the work of Santini et al. (3) , who noted that EGFR expression was frequently observed only in breast cancers with a high nuclear grade that also expressed basal epithelial markers (3) . In a more recent study, long-term treatment of basal mammary epithelial cells with EGF resulted in a mobile rather than a stationary phenotype (4), possibly indicating a mechanism by which expression of EGFR influences the behavior of breast cancer cells that possess a basal epithelial phenotype.
One question raised by these observations is whether the basal phenotype of BRCA1-related breast cancer reflects the possible cell of origin of these tumors (5), or instead, the presence of CK5/6 merely represents a particular pattern of differentiation, uncoupled from histogenesis (6) 
